<DOC>
	<DOCNO>NCT01472029</DOCNO>
	<brief_summary>The purpose study determine rate complete pathological response ( percentage patient pCR refer total number enrol eligible patient ) , evaluate centrally reference pathologist .</brief_summary>
	<brief_title>Explorative Phase II Study Perioperative Treatment Patients With Adenocarcinoma Gastroesophageal Junction Stomach</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm adenocarcinoma gastroesophageal junction ( AEG IIII ) stomach ( uT2 , uT3 , uT4 , N category , M0 ) , T N+ M0 patient , follow specification : Endosonography esophagealgastroduodenoscopy ; Categorization gastroesophageal junction tumor accord classification Siewert ( 1987 , cf . appendix 2 ) Detection adenocarcinoma HER2 3+ ( IHC ) HER2 2+ ( IHC ) amplification proven FISH , SISH CISH accredit local pathologist ( quality assurance tumor sample available subsequent central review ) No precede cytotoxic target therapy Male female patient age ≥ 18 year . If able reproduce , patient must willing use highly effective method contraception treatment 6 month end treatment ( adequate : method fulfil requirement Note guidance nonclinical safety study conduct human clinical trial pharmaceutical [ CPMP/ICH/286/95 mod ] ) . Female patient reproductive ability must perform negative pregnancy test within 7 day study entry . ECOG ≤ 2 Exclusion distant metastasis CT thorax abdomen , bone scan MRI ( osseous lesion suspect due clinical sign ) Laparoscopic exclusion peritoneal carcinomatosis , suspect clinically Adequate haematological , hepatic renal function parameter : Leukocytes ≥ 3000/mm³ , platelet ≥ 100,000/mm3 ; Serum creatinine ≤ 1.5 x upper limit normal , GFR &gt; 40 ml/min ; Bilirubin ≤ 1.5 x upper limit normal , AST ALT ≤ 3.5 x upper limit normal , alkaline phosphatase ≤ 6 x upper limit normal Normal cardiac ejection fraction , assess echocardiography Written patient consent form Known hypersensitivity trastuzumab , murine protein , 5FU , leucovorin , oxaliplatin docetaxel Other know contraindication trastuzumab , 5FU , leucovorin , oxaliplatin , docetaxel Clinically significant active coronary heart disease , cardiomyopathy congestive heart failure , NYHA IIIIV Clinically significant valvular defect Past current history malignancy curatively treat without evidence disease 5 year , except curatively treat basal cell carcinoma skin situ carcinoma cervix Known brain metastasis Severe dyspnoea rest due complication advance malignancy require supplementary oxygen therapy Other severe internal disease acute infection Peripheral polyneuropathy &gt; NCI Grade II Chronic inflammatory bowel disease Ontreatment participation another clinical study period 30 day prior inclusion study Subject pregnant breast feeding , plan become pregnant within 6 month end treatment Patients close institution accord authority court decision ( AMG § 40 , Abs . 1 No . 4 ) Any concurrent antineoplastic treatment include irradiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Gastroesophageal junction</keyword>
	<keyword>Stomach</keyword>
	<keyword>HER2</keyword>
</DOC>